FolotynActive Ingredient(s): Pralatrexate
FDA Approved: * September 24, 2009
Pharm Company: * ALLOS THERAPEUTICS, INC
Pralatrexate, sold under the brand name Folotyn, is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Pralatrexate was approved for medical use in the United States in September 2009, as the first treatment for Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma. Contents 1 Medical uses 2 Mechanism 3 Discovery 4 Society and culture 4.1... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Wanting seek out for more information re: Folotyn, my dad will begin using this drug soon and I want to educate myself. ...